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Abstract: In this work we studied the functional differences between the microcirculation of murine tumours 
that only express single isoforms of vascular endothelial growth factor-A (VEGF), VEGF120 and VEGF188, 
and the effect of VEGF receptor tyrosine kinase (VEGF-R TK) inhibition on their functional response to the 
vascular disrupting agent, combretastatin A-4 phosphate (CA-4-P). We used measurement of fluorescently-
labelled red blood cell (RBC) velocities in tumour microvessels to study this functional response. RBC 
velocity for control VEGF120-expressing tumours was over 50% slower than for control VEGF188-
expressing tumours, which may be due to the immature and haemorrhagic vasculature of the VEGF120 
tumour. After chronic treatment with a VEGF-R tyrosine kinase inhibitor, SU5416, RBC velocities in 
VEGF120 tumours were significantly increased compared to control VEGF120 tumours, and similar to 
velocities in both VEGF188 treatment groups. Control and SU5416 treated VEGF188 tumours were not 
different from each other. Treatment of VEGF120 tumours with SU5416 reduced their vascular response to 
CA-4-P to a similar level to the VEGF188 tumours. Differential expression of VEGF isoforms not only 
affected vascular function in untreated tumours but also impacted on response to a vascular disrupting drug, 
CA-4-P, alone and in combination with an anti-angiogenic approach involving VEGF-R TK inhibition. 
Analysis of RBC velocities is a useful tool in measuring functional responses to vascular targeted treatments. 
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1. Introduction 
 
 Vascular endothelial growth factor-A 
(commonly known as VEGF)(Ellis & Hicklin, 
2008) is the predominant protein involved in 
normal and tumour angiogenesis, a process 
crucial for the supply of oxygen, nutrients and 
growth factors to tumours (Folkman, 1990). 
The VEGF gene undergoes alternative 
splicing to produce multiple functional 
isoforms, such as 121, 165 and 189 in human 
(Tischer et al., 1991) and 120, 164, and 188 
in the mouse (Shima et al., 1996). 
Fibrosarcoma cell lines have been developed 
to express single isoforms of VEGF and used 
to study their roles in tumour vascularisation. 
Tumours expressing only VEGF120 are well 
vascularised, but present with immature blood 
vessels that are fragile and leaky and the 
tumours are prone to haemorrhage, 
particularly when grown in the dorsal skin-
flap window chamber model, where vessels 
struggle to penetrate beyond the tumour edge 
(Tozer et al., 2008). VEGF188 expressing 
tumours have a lower vascular volume than 
VEGF120 tumours, but the blood vessels are 
much more mature, showing good levels of 
pericyte coverage and less haemorrhage 
(Tozer et al., 2008).  
 
Vascular disrupting agents (VDAs) are a 
group of compounds that selectively target 
tumour vasculature and cause a devastating 
collapse of blood flow in solid tumours, 
culminating in tumour cell death. It is thought 
2nd Micro and Nano Flows Conference 
West London, UK, 1-2 September 2009 
- 2 - 
that VDAs preferentially target immature 
tumour blood vessels, with most evidence 
derived from VDAs that are tubulin-binding 
and endothelial cytoskeleton disrupting 
(Tozer et al., 2005b). Disodium 
combretastatin A4 3-O-phosphate (CA-4-P) is 
the lead tubulin-binding VDA and studies 
have shown that VEGF120 tumours that 
present with immature vessels showed 
reduced vascular and growth response to CA-
4-P, compared with VEGF188 tumours that 
possess a more mature vascular network 
(Tozer et al., 2008). 
 
The VEGF receptor family of proteins belong 
to the protein tyrosine kinases that regulate 
multiple cellular processes that contribute to 
tumour development and progression, 
including cell proliferation, differentiation 
and cell survival (Baselga, 2006, Blume-
Jensen & Hunter, 2001), and many human 
tumours exhibit aberrant tyrosine kinase 
activity that drives their growth.  Tyrosine 
kinase inhibitors therefore represent attractive 
anti-tumour or anti-vascular targets in the 
clinic (Arteaga, 2003, Baselga, 2006). Several 
multi-target tyrosine kinase inhibitors that 
include targeting VEGF receptors have 
reached clinical practice or are in clinical trial 
(Faivre et al., 2007, Drevs et al., 2007). 
Under some dosing strategies, treatment with 
VEGFR-2 receptor antibodies or small 
molecule inhibitors can result in tumour 
vascular ‘normalisation’, whereby vascular 
morphology is altered and blood flow is 
improved over a limited time-frame (Winkler 
et al., 2004, Jain, 2003, Jain, 2005). However, 
very little is known about how chronic 
tyrosine kinase inhibitors affect the function 
and morphology of the surviving blood 
vessels in tumours, and how this affects 
subsequent treatment stratagems. We sought 
to investigate the effects of tyrosine kinase 
receptor inhibition on the development of 
tumours expressing single isoforms of VEGF, 
and their subsequent response to CA-4-P 
treatment.  
 
2. Methods 
 
All experiments were conducted in 
accordance with the United Kingdom Home 
Office Animals (Scientific Procedures) Act 
1986 and with local ethical approval. CA-4-P 
was kindly provided by Professor GR Pettit, 
Arizona State University. 
 
2.1 VEGF isoform cell lines and tumours 
 
Development of cell lines is described 
previously (Tozer et al., 2008), but briefly, 
primary mouse embryo fibroblasts expressing 
only single isoforms of VEGF (120, 164 or 
188) or all isoforms were isolated from 13.5 
days post-coitum (dpc) embryos produced by 
heterozygous breeding pairs of single VEGF 
isoform-expressing mice on a Swiss 
background. Fibroblast cultures were 
genotyped, as described (Vieira et al., 2007), 
to identify wild-type samples and those 
homozygous for the Vegfa120, Vegfa164 or 
Vegfa188 allele. Fibroblasts were immortalised 
and oncogenically transformed by retroviral 
transduction with SV40 and HRAS (h-ras) 
(Parada et al., 1984, Greco et al., 2005). In 
this study we used only VEGF120 and 188 
tumours as they present with the widest 
functional and morphological diversity for 
comparison.  
 
2.2 Window Chambers  
 
All surgery was carried out on male severe 
combined immunodeficiency (SCID) mice 
(12-16 week-old, 28-32g) under general 
anaesthesia using intraperitoneal (i.p) 
injection of fentanyl citrate (0.8mg•kg-1) and 
fluanisone (10mg•kg-1; Hypnorm, Janssen 
Animal Health) and midazolam (5mg•kg-1; 
Hypnovel, Roche, Welwyn Garden City, 
UK). Animals were kept warm during 
surgical procedure, and aseptic technique was 
used throughout. Surgical procedures are 
similar to those described previously (Tozer 
et al., 2005a). Briefly, animals were shaved, 
depilated and a 15 mm diameter circular area 
of dorsal skin was removed, as well as the 
subcutaneous (s.c.) fat and connective tissue 
of the opposing skin layer, leaving the 
exposed panniculus muscle. An aluminium 
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window chamber (total weight ∼2g), designed 
to hold two parallel windows, was implanted 
onto the dorsal skin. A tumour fragment (∼0.5 
mm in diameter, either VEGF120 or 188) 
from a donor animal was implanted onto the 
exposed panniculus muscle and the chamber 
was closed with a glass window to provide a 
depth of 200 µm for tumour growth. Sub-
cutaneous dextrose saline and intraperitoneal 
buprenorphine (Vetergesic) were used to aid 
recovery and animals were kept in a warm 
room, 28-30 °C, until the day of experiment. 
Animals were grouped for treatment and 
received either the VEGF-R tyrosine kinase 
inhibitor, SU5416 (50 mg•kg-1, at a 
concentration of 25 mg•ml-1 subcutaneously) 
or vehicle control (50 µl of DMSO per 
mouse) as used previously (Fong et al., 1999) 
starting at day 3 after implant, and then given 
every 4th day until further experimentation.  
 
2.3 Red Blood Cell labelling  
 
Donor red blood cells (RBC) were obtained 
via cardiac puncture from donor male SCID 
mice and labelled with the fluorescent dye 
1,1', di-octadecyl-
3,3,3'3'tetramethylindocarbocyanine perchlorate 
(DiI) (Molecular Probes, Cambridge 
Biosciences, UK) for the measurement of 
RBC velocity in the tumour vasculature. The 
labelling method has been published 
previously (Unthank et al., 1993), but briefly 
the RBCs were separated from blood plasma 
and white blood cells by centrifugation and 
the isolated and washed RBCs incubated with 
DiI for 30 mins. 25 µg of DiI was used per 50 
µl of packed RBCs. After incubation the 
RBCs were washed and resuspended in 
phosphate buffered saline (50 µl•ml-1 RBC-
DiI complex). The labelled cells were kept for 
3 days at 4°C.  
 
2.4 Intravital Microscopy  
 
Intravital microscopy permits the observation 
of RBC movement in microvessels of small 
animals under both normal and pathological 
conditions (Sandison, 1924). The analysis of 
RBC velocities is used in many areas of 
research, to measure the responsiveness to 
vasoactive drugs (Prazma et al., 1989) or 
response to vascular disrupting agents (Tozer 
et al., 2001). Approximately 7-11 days after 
surgery, when the tumours reached ∼3.0 mm 
in diameter, mice were given 0.2 ml (i.v.) of 
the RBC-DiI complex and treated with a 
single dose of the vascular disrupting agent, 
CA-4-P (30mg•kg-1, iv at a concentration of 3 
mg•ml-1 in 0.9 % NaCl) and monitored for 24 
hours to observe changes in RBC velocity. An 
inverted Nikon Eclipse E600FN fluorescence 
microscope with modified stage to take mice 
was used. Tumours were viewed at various 
time points over the 24 hrs after treatment (0, 
2.5, 15, 30 and 60 mins, and 3, 6 and 24 hrs) 
under transmitted light for morphological 
vessel analysis, and then under epi-
fluorescence illumination using a 100 W 
mercury arc lamp for measurement of RBC 
velocity, where videos were taken for 60s at 
each time point for analysis. Fluorescence 
was set up to excite at 550nm and detect the 
emissions at 565nm from the labelled RBCs 
using a custom-made fluorescence cube 
(Nikon, UK). 
 
2.5 Velocity Analysis 
 
RBC velocities were calculated from data 
recorded at x20 magnification with the same 
region of interest used at each time point. 
Velocities were calculated using a keyhole 
tracking algorithm performed in Matlab, as 
described previously (Reyes-Aldasoro et al., 
2008). 
 
The tracking algorithm consisted of three 
main steps: pre-processing which transformed 
the videos into a sequence of binary images 
that contained segmented foreground objects 
(RBCs). Computational complexity (number 
of operations and time required to process) 
was reduced by reducing the number of pixels 
processed: alternate rows were discarded and 
for every row, contiguous pixels were 
averaged and their mean value assigned to a 
new pixel. Besides reducing the dimensions, a 
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smoothing effect was produced and noise was 
reduced. Intensity inhomogeneity was 
removed by equivalent background 
subtraction and artefacts, such as the labels on 
the screen were removed with a mean image 
of the temporal sequence. The centroids of the 
RBCs were determined together with the 
distances that separated them from 
neighbours, if any. Tracking, which linked the 
objects in contiguous frames to form the 
tracks by means of a keyhole model, which 
predicted the most probable landing position 
of a RBC at time t+1 from the position in 
times t-1 and t. The most probable step for a 
RBC that is moving from frame t-1 to frame t, 
is to follow the direction of the previous steps 
with the same velocity to frame t+1. If we 
assume that a child RBC will move with the 
same direction and velocity as its parent, we 
can predict its landing position. Of course, 
this would not cover changes in speed, turns 
in vessels or even simple movements within a 
wide vessel. Two regions of probability 
where the RBC is most probable to land were 
therefore defined: a narrow wedge (60° wide) 
oriented towards the predicted landing 
position, and a truncated circle (300°) that 
complements the wedge; together they 
resemble a keyhole. Once all segmented 
RBCs had been examined for possible parent-
child relationships, a reduced number of them 
formed a series of tracks of different lengths. 
Post-processing removed links in tracks that 
could have resulted from noise, and joined 
sections that were considered to be split 
sections from a single track. The same 
keyhole model was used analysing the 
movement backwards. That is, the same 
keyhole model used child (t+1) and 
grandchild (t+2) to generate a keyhole at time 
(t). If the RBC of a previous time point was 
found to land inside the keyhole, it remained 
as part of the track, otherwise it was removed. 
Finally outliers were removed: those tracks 
whose average velocity exceed 3 times the 
standard deviation from the mean average 
velocity of the whole distribution were 
discarded.  
 
This process relies on the probability of RBC 
movement and allows analysis of all cells 
over a time period rather than a select few. 
 
 Velocity was calculated at µm•s-1 from the 
number of video frames taken for each red 
cell to travel between two points of measured 
distance. The average was weighted 
according to the length of each track to avoid 
biasing from small tracks. Fig. 1a shows a 
sample fluorescence image where the bright 
spots describe RBCs and colour lines describe 
the tracks that were detected at that frame (the 
tracks spanned several frames) and Fig. 1b 
shows all the tracks detected for a video 
sequence. 
 
2.6 Statistics 
 
Statistical analysis was performed using SPSS 
version 11.0.2 for the Apple Macintosh.  
Data are presented as mean ± standard error 
of the mean. Student’s unpaired t-test was 
used to test for significant differences 
between two groups. Time-course 
experiments were measured using a mixed 
design ANOVA for repeated measures with 
between subjects factors used for tumour type 
and VEGF-R tyrosine kinase receptor 
inhibitor treatment, followed by Tukey (HSD) 
post-hoc tests correction. 
 
3. Results 
 
At the 0 min time-point, immediately prior to 
CA-4-P injection, the RBC velocity of 
VEGF120 tumours treated with vehicle was 
188 ± 4 µm•s-1 which was significantly lower 
than the VEGF-R tyrosine kinase inhibitor-
treated VEGF120 tumours, 389 ± 7 µm•s-1 
and both VEGF188 tumour groups (untreated, 
354 ± 7 µm•s-1 and treated 344 ± 6 µm•s-1). 
There was no significant difference with tests 
between any of the pairs from the three 
experiments VEGF188 control, VEGF188 + 
SU5416 and VEGF120 + SU5416 (Fig. 2). 
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Fig 1 Tracks obtained from a video sequence. 
(a) A single frame with several RBCs and 6 
tracks detected at this frame. (b) All the tracks 
detected in the video as a 3D plot with time as 
the z-axis. Colour of the tracks denotes the 
velocity 
 
 
 
The time-course of RBC velocity response to 
CA-4-P, for the different tumour types ± 
SU5416 treatment, is shown in Figure 3. 
Control VEGF120 tumours without SU5416 
pre-treatment, were much more responsive to 
CA-4-P than VEGF188 tumours, as shown 
previously (Tozer et al., 2008).  
 
 
Fig. 2 Quantitative analysis of average RBC 
velocity of tumours grown within the dorsal 
skin-flap window chamber, just prior to CA-
4-P treatment. Results indicate that the 
receptor tyrosine kinase inhibitor, SU5416, 
significantly increased RBC velocity in 
VEGF120 tumours to similar levels as 
VEGF188 tumours. SU5416 treatment had no 
effect on RBC velocity in VEGF188 tumours. 
* represents P < 0.05 significance compared 
to VEGF120 untreated tumours.  
 
In VEGF120 tumours, RBC velocity was 
reduced to approximately 20% of its pre-
treatment value by 3 hours after CA-4-P and 
did not recover within 24 hours, whereas, in 
VEGF188 tumours, RBC velocity was 
reduced to no more than 60% of pre-treatment 
level and fully recovered to pre-treatment 
level by 24 hours. However, SU5416 pre-
treatment significantly reduced the effect of 
CA-4-P in the VEGF120 tumours (P < 0.05) 
(Fig. 3a), such that RBC velocity had returned 
to control values by 3 hours after CA-4-P 
treatment. In VEGF188 tumours, SU5416 
pre-treatment also significantly decreased the 
RBC velocity response to CA-4-P (P < 0.05), 
even though this tumour type was intrinsically 
more resistant to CA-4-P than the VEGF120 
tumours (Fig. 3b).  
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Fig. 3 Quantitative analysis RBC velocities of 
tumours grown in the dorsal skin-flap window 
chamber. Repeated measures analysis indicate 
significant differences between treatment 
groups for both VEGF120 and VEGF188 
tumours for RBC velocities. * represents P < 
0.05 for the difference between groups 
receiving VEGF-R TK inhibition and vehicle 
controls. 
 
Between subjects comparison of VEGF120 
and VEGF188 tumour responses indicates 
that untreated tumours were significantly 
differently from each other across the 24 hr 
time course for RBC velocities (F1,16 = 8.62, 
P < 0.05) whereas the responses of tumour 
lines treated with SU5416 were not 
significantly different from each other. It was 
also found that the responses of SU5416 
treated VEGF120 tumours were not 
significant from the untreated VEGF188 
tumour (Fig. 3). 
 
4. Conclusions 
 
Treatment with CA-4-P caused significant 
reduction in RBC velocity, with no recovery 
over 24 hours, in VEGF120 tumours, whereas 
VEGF188 tumours were much more resistant. 
However, pre-treatment with the tyrosine 
kinase VEGF receptor inhibitor, SU5416, 
modified the vasculature of VEGF120 
tumours, such that RBC velocity was 
increased and response to CA-4-P was 
reduced. SU5416 had no effect on RBC 
velocity of VEGF188 tumours but also 
reduced their response to CA-4-P.  
 
These data support the notion that presence of 
VEGF188 in tumours confers a level of 
protection from the effects of CA4P. It is 
thought that these tumours have a more 
mature stable vasculature which contributes 
to this protection (Tozer et al., 2008). The 
immature blood vessels in VEGF120 tumours 
are rapidly broken down. Tyrosine kinase 
inhibition with SU5416 significantly 
increased RBC velocity in individual vessels 
of VEGF120 tumours, which was 
accompanied by decreased vascularization 
(data not shown). SU5416 and similar agents 
were designed to block tumour angiogenesis 
by interfering with VEGF-mediated effects 
such as endothelial proliferation and 
migration. However, the current results 
support existing evidence that a sub-optimal 
anti-angiogenic effect can result in a rarefied 
tumour vascular bed, which nevertheless is 
efficiently perfused and capable of sustaining 
tumour growth (vascular normalization) (Jain, 
2005). In addition, we show that vascular 
normalization can reduce the efficacy of the 
so-called vascular disrupting agents (VDAs), 
which are designed to target the established 
tumour vasculature. Further studies are 
required to investigate the vascular 
morphological changes that take place as a 
result of tyrosine kinase inhibition. It is 
possible that there is an increase in pericyte 
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coverage of these vessels, which would imply 
improved support and resistance against CA-
4-P treatment. VEGF188 tumour response to 
CA-4-P was also reduced following SU5416 
alone treatment, despite no effect of SU5416 
on RBC velocity, and this result requires 
further mechanistic investigation, including 
analysis of vascular morphology.  
  
This study shows that vascular normalization 
following anti-angiogenic treatment with a 
VEGF-R tyrosine kinase inhibitor can have 
unexpected consequences for subsequent 
treatment outcome. Analysis of RBC 
velocities in tumours, using the novel 
algorithm described, is a useful tool in 
measuring functional responses to vascular-
targeted treatments. 
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